Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Kings College Hospital

Skip to Main Content

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization


Open to: All Genders

Age: 45 Years - 99 Years

Medical Conditions

Critical Limb Ischemia (CLI)

Study summary

This will be a randomized, placebo-controlled, parallel group, multicenter, Phase III study.The study aims to evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor Tissue Loss (Rutherford Category 5) who are Unsuitable for Revascularization.

Key dates

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

May 2017

Dec 2021

Study type


Intervention Type : Biological
Intervention Name : PLX-PAD
Intervention Description : Local intramuscular (IM) injections of PLX-PAD in the index leg.

Intervention Arm Group : PLX-PAD

Intervention Type : Biological
Intervention Name : Placebo
Intervention Description : Local intramuscular (IM) injections of Placebo in the index leg.

Intervention Arm Group : Placebo

Who can take part?

You can take part if:

Inclusion Criteria:

1. Adult male or female subjects between ages 45-99 years of age.

2. CLI, with minor tissue loss up to the ankle level (Rutherford Category 5)

3. Ankle pressure (AP) ≤70 mmHg or TP ≤50 mmHg in the index leg. (If a subject has ABI >1.4 and TP is not measureable, inclusion may be based on TcPO2 ≤30 mmHg)

4. Subject unsuitable for revascularization (by any method) in the index leg.

5. Ischemic lesions in the index leg stable for at least 2 weeks.

6. Ischemic ulcers in the index leg without tendon or bone exposure (unless secondary to a minor amputation).

7. Under treatment for cardiovascular risk factors: hypertension, hyperlipidemia, diabetes, in accordance with applicable guidelines. Concomitant therapy with a statin and an anti-platelet agent for at least 2 weeks prior to randomization.

8. Women of childbearing potential must have a negative serum pregnancy test at screening and must be willing to use at least one highly effective birth control method throughout the study.

9. Signed informed consent form.

Exclusion Criteria:

1. Non-atherosclerotic PAD (e.g. Buerger's disease).

2. CLI with major tissue loss (Rutherford Category 6) in either leg.

3. Evidence of active infection (e.g., cellulitis, osteomyelitis).

4. Subject having undergone surgical revascularization or major amputation less than 1 month prior to screening, or endovascular revascularization or minor amputation less than 2 weeks prior to screening.

5. Planned or potential need for major/minor amputation or any revascularization within 1 month of study entry upon investigator's judgment.

6. Aorto-iliac stenosis or common femoral artery stenosis ≥70%, or otherwise suspicion of inadequate inflow to the leg.

7. Life expectancy of less than 6 months.

8. Stroke or acute myocardial infarction/unstable angina within 3 months prior to screening.

9. Severe congestive heart failure symptoms (New York Heart Association [NYHA] Stage IV).

10. Uncontrolled severe hypertension.

11. Diabetes mellitus with HbA1c >10%.

12. Current or history of proliferative retinopathy.

13. Known Hepatitis B virus or Hepatitis C virus or acquired immunodeficiency syndrome (AIDS) infections.

14. Subjects with international normalized ratio (INR) >2.5.

15. Subject on renal replacement therapy or with eGFR <15 mL/min/1.73m2.

16. Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending another investigational device or drug trial(s), unless in long-term follow-up phase.

17. Use of hyperbaric oxygen therapy, prostanoids, spinal cord stimulation, lumbar sympathectomy, wound dressing containing cells or growth factors, or topical platelet derived growth factor.

18. Known allergies to any of the following: DMSO, human serum albumin, bovine serum albumin.

19. History of allergic/hypersensitivity reaction to any substance having required hospitalization and/or treatment with IV steroids/epinephrine.

20. Pulmonary disease requiring supplemental oxygen treatment on a daily basis.

21. Active malignancy or history of malignancy within 5 years prior to study entry.

22. In the opinion of the investigator, the subject is unsuitable for participating in the study.

23. Inability to understand and provide an informed consent.

You may not be able to take part if:

This is in the inclusion criteria above

Where can I take part?

Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Kings College Hospital
    SE5 9RS
  • Vascular Research Clinical Research Centre Beaufort Way Southmead Hospital Westbury on Trym Bristol
    BS10 5NB
  • Hull And East Yorkshire Women And Children's Hospital-Hull And East Yorkshire Hospitals Nhs Trust
  • Department of Vascular Research, St George's Hospital
    SW17 0QT


The study is sponsored by Pluristem Ltd. .

We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.

Is this study information helpful?

What will you do next?

Read full details

for Trial ID: NCT03006770

Last updated

This page is to help you find out about a research study and if you may be able to take part

The information is provided by researchers and we rely on them to keep it up-to-date. You can see more information by clicking on the 'Read full details' link above.

To take part, please print or share the study information with your GP/healthcare provider or contact the research team directly.